John Androsavich, PhD, Pfizer
![Dr. John Androsavich](/sites/default/files/2022-11/Screenshot%202022-11-21%20at%203.09.24%20PM.png)
Dr. John Androsavich joined Pfizer as Global Head, RNA Medicine Lead in October
2021. Prior to Pfizer, Dr. Androsavich served as Senior Director of Pulmonary and Liver
Research at Translate Bio, a mRNA/LNP therapeutics company. He also held research
positions at RaNA Therapeutics and Regulus Therapeutics. In these roles, Dr.
Androsavich was responsible for leading pipeline programs from target
identification/portfolio strategy to early discovery through IND-stage with a focus on rare
diseases. Dr. Androsavich has 15 years of experience in RNA research across multiple
RNA therapeutic platforms including ASOs, siRNAs, lncRNAs, miRNAs, and
mRNA/LNPs. He received his undergraduate degree in Biology from the University of
Pittsburgh and his PhD in Chemical Biology from the University of Michigan.